Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

149P - Molecular and clinical characteristics of patients with resectable gastric cancer

Date

22 Nov 2020

Session

e-Poster Display Session

Topics

Tumour Site

Gastric Cancer

Presenters

Zhi Zheng

Citation

Annals of Oncology (2020) 31 (suppl_6): S1287-S1318. 10.1016/annonc/annonc356

Authors

Z. Zheng1, J. Yin1, H. Cheng2, H. Wang2, F. Lou2, S. Cao2, J. Zhang1

Author affiliations

  • 1 General Surgery, Beijing Friendship Hospital, Capital Medical University., 100050 - Beijing/CN
  • 2 Department Of Medicine, Acornmed Biotechnology Co., Ltd., 100176 - Beijing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 149P

Background

Gastric cancer (GC) is one of the most common malignancies and a leading cause of cancer deaths worldwide. Currently, the genomic researches mainly focused on metastatic GC, but the clinico-molecular characteristics of resectable GC were poorly investigated.

Methods

A total of 47 resectable GC patients were enrolled. All kinds of genomic mutations were identified by next-generation sequencing (NGS) with Acornmed panel. Programmed death-ligand 1 (PD-L1) expression was analyzed by immunohistochemistry staining.

Results

Overall, a total of 582 mutations were identified from all the patients. TP53, LRP1B, ARID1A, and MDC1 were the most commonly mutated genes in resectable GC. Genomic data revealed significant mutual exclusivity between alterations in TP53 and PIK3CA (p < 0.05) and between those in TP53 and DICER1 (p < 0.05), as well as mutual co-occurence between alterations in FAT1 and ERBB3 (p < 0.05) and between those in FAT1 and NOTCH2 (p < 0.05). Additionally, ARID1A and APC alterations were significantly associated with poor differentiation (p < 0.05), and frequency of ARID1A mutations was markedly higher in intestinal-type GC than diffuse GC (p < 0.05). PD-L1 expression was analyzed in 45 tumors, and 33.3% of them showed positive PD-L1 expression. Further analysis demonstrated that KMT2D and ARID1A alterations were strikingly correlated with positive PD-L1 expression (p < 0.05). The median tumor mutational burden (TMB) in resectable GC was 6.38 mutations/Mb, and AR, CDH1, NOTCH2, and FAT1 mutations were remarkably associated with high TMB (p < 0.05). We further found that patients with positive PD-L1 expression tended to have low TMB (p = 0.057).

Conclusions

This study is of great significance in understanding the population characteristics of patients with resectable GC, which will be useful to guide personalized therapy and promote the clinical management in this population.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Zhi Zheng.

Funding

Beijing Municipal Science & Technology Commission.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.